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ABSTRACT
Background. Controversy exists on the relationship between iron metabolism and
cardiometabolic risk. The aim of this study was to determine if there is a link between
dysmetabolic iron and cardiometabolic markers in subjects with excess body weight.
Methods. Cross-sectional study with fifty participants presenting overweight or obesity
and at least another metabolic syndrome factor. Determinations: anthropometry, body
composition, blood pressure, lipids, glucose, insulin, leptin, areas under the curve
(AUC) for glucose and insulin after an oral glucose tolerance test, hs-C reactive protein
(hs-CRP), blood count, ferritin, transferrin, transferrin saturation (TSAT), soluble
transferrin receptor (sTfR). Gender-adjusted linear correlations and two independent
samples t tests were used.
Results. Ferritin was positively correlated with insulin-AUC (r = 0.547, p= 0.008) and
TSAT was negatively correlated with waist-hip ratio (r =−0.385, p= 0.008), insulin
(r =−0.551, p< 0.001), and insulin resistance (HOMA-IR, r =−0.586, p< 0.001).
Subjects with TSAT ≤ 20% had higher insulin (p= 0.012) and HOMA-IR (p= 0.003)
compared to those with TSAT > 20%. In conclusion, the observed results suggest that
iron transport and storage are altered in subjects with overweight/obesity, at the same
time that they exhibit the characteristic features of insulin resistance. Nevertheless, this
occurs without iron overload or deficiency. These results should be validated in wider
cohorts since they suggest that iron transport and storage should be assessed when
performing the clinical evaluation of subjects with excess body weight.
Subjects Biochemistry, Diabetes and Endocrinology, Nutrition, Public Health
Keywords Iron, Ferritin, Tranferrin, Insulin resistance, Obesity
INTRODUCTION
The worldwide epidemic of obesity that affects both industrial and developing
countries (NCD Risk Factor Collaboration, 2016) clearly has a multifactorial origin,
therefore requiring a multidisciplinary approach. Overweight and obesity are the result
of an imbalance between energy intake and expenditure, but they also involve a complex
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phenomenon of endocrine disruption signals. Obesity is one of the defining factors of
metabolic syndrome (MetS), which is characterised by a cluster of factors also including
excessive abdominal fat, dyslipaemia, hypertension, and insulin resistance (Alberti et al.,
2009).
Within this context, different studies have detected iron deficiency in obesity; this has
been mainly attributed to the inflammatory status characteristic of excessive adipose tissue
involving an elevation of proinflammatory cytokines such as hepcidin, which reduces
iron absorption (Tussing-Humphreys et al., 2009; Aigner, Feldman & Datz, 2014; Zhao et
al., 2015). In contrast, other reports show moderate to high levels of body iron in patients
with cardiovascular diseases and type 2 diabetes (T2DM) (Zacharski et al., 2017), as well
as associations between high ferritin and high triglycerides with low HDL-cholesterol in
T2DM and patients with type 1 diabetes (Vaquero et al., 2017). Indeed, since iron activates
many oxidative processes, excessive free iron may contribute either to the onset or to the
aggravation of these pathologies. Therefore, if excess of iron is a contributing factor to
cardiometabolic alterations, a reduction of its body levels should be beneficial. In this
line, a reduction of body iron stores induced by phlebotomies decreased blood pressure
and markers of cardiovascular risk, also improving glycaemic control, in patients with
MetS (Houschyar et al., 2012). However, in patients with iron overload the benefit of this
procedure compared to dietary and lifestyle intervention has not been proved (Laine et al.,
2017). On the contrary, if iron deficiency coexists with obesity and contributes to fatigue,
low physical performance, etc., iron supplementation should be promoted, but this has not
been demonstrated and the issue is controversial. Another important aspect is that iron is
a very well-known factor that increases food intake, which may increase body weight and
adiposity in predisposed individuals, and, in this regard, one study suggested a relationship
between adipocyte iron and appetite mediated by leptin, the satiety hormone (Gao et al.,
2015).
Therefore, the complex metabolic alterations implicated in the MetS, with obesity as a
key initial factor, may include dysmetabolic iron, although the specific direction of this
alteration—excess or deficit—is not completely known and the role of iron in subjects with
MetS, obesity, or diabetes is still limited and not conclusive.
Thus, the aim of this exploratory study was to evaluate the relationship between iron
status parameters and both cardiometabolic risk factors as insulin resistance indexes in




This human study was conducted according to the Declaration of Helsinki guidelines.
The participants were recruited in Madrid (Spain) and signed a written informed
consent approved by the Ethics Committees of Hospital Puerta de Hierro-Majadahonda
(2016/12/02) and the Spanish CSIC (2016/12/13). The design was a cross-sectional
analytical study, part of the registered clinical trial NCT03076463. Inclusion criteria
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were: age ≥18 and <70 years, apparently healthy and presenting body mass index (BMI)
>25 kg/m2 and at least another MetS factor (fasting glucose≥ 100 mg/dL; HDL-cholesterol
≤ 50 mg/dL in women and 40 mg/dL in men; triglycerides ≥ 150 mg/dL; systolic pressure
≥ 130 mmHg or diastolic pressure ≥ 85 mmHg). Exclusion criteria were: diagnosis of any
cardiometabolic pathologies, e.g., T2DM; any previous cardiometabolic event, e.g., heart
stroke; any medication related to cardiometabolic pathologies or risk factors, e.g., statins
or angiotensin-converting enzyme inhibitors; any medication that may affect lipid profile;
pregnancy; lactation.
Sample size was calculated using the G*Power software for bivariate normal models.
The primary outcome variable for sample size calculation was the modification in the
HOMA-IR (homeostatic model assessment for insulin resistance) index. Based on previous
studies (Vaquero et al., 2017; Ebron et al., 2015), assuming a coefficient r = 0.40, α= 0.05
and statistical power (1−β) = 0.80, a sample size of 46 was needed. Fifty subjects were
recruited, and finally 49 subjects participated. Volunteers attended the Human Nutrition
Unit of our institute for fasting analyses and, due to logistic reasons, an oral glucose
tolerance test (OGTT) was performed on 25 randomly selected subjects.
Blood pressure, body weight, height, waist-hip ratio (WHR), and waist to height
ratio (WHtR) were measured by standardized procedures and BMI was calculated. Body
composition was estimated by bioimpedance (Tanita BC-601, Arlington heights, IL, USA).
Blood samples were collected to determine: haematocrit, mean corpuscular volume (MCV),
haemoglobin, red blood cell distribution width (RDW), serum iron, serum transferrin,
glucose, lipids, high sensitive C-reactive protein (hs-CRP), and serum ferritin, all by
autoanalyzer. Serum soluble transferrin receptor (sTfR) was determined by ELISA (DRG
Instruments GmbH, Marburg, Germany).
Food intake was assessed by three 24 h dietary recalls performed by telephone interviews
(two in working days and one in the weekend) several days before blood sampling. They
were performed by a dietitian, for about 10 min, the morning after the day that was
registered. In order not to originate a modification in dietary habits, the subjects did not
know in advance when they would receive the call. No diet record diaries had to be filled
by volunteers. Daily energy intake, nutrient intake and energy provided by macronutrients
were calculated with the computer program DIAL (Alce Ingeniería) using the Spanish
Food Composition Database (Ortega et al., 2013).
An oral glucose tolerance test (OGTT) using a 75 g glucose solution was performed in
a subsample of 25 volunteers randomly selected. Serum samples were collected at 0, 30, 60
and 120 min. Glucose was analysed by the Free Style Optimum Neo blood glucose meter
(Abbott, Chicago, IL, USA) and insulin and leptin by ELISA assays (Merck-Millipore,
Burlington, MS, USA). In the case of the insulin kit (EZHI-14K), the standard curve range
was 2–200 µU/mL and the limit of detection was 1 µU/mL. In the case of the leptin kit
(EZHL-80SK), the standard curve range was 0.5–100 ng/mL and the limit of detection was
0.2 ng/mL.
Calculations
Total iron binding capacity (TIBC) = 25.1 × transferrin (g/L).
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Transferrin saturation (TSAT) = serum iron (µmol/L)/TIBC (µmol/L) × 100.
Insulin resistance was estimated by HOMA-IR = (glucose, mg/dL × insulin, µU/mL)
/405.
Areas under the curve (AUC) of glucose and insulin were calculated from the values
obtained at 0, 30, 60 and 120 min of the OGTT test using the trapezoid method.
Statistical analyses
The distribution of the variables was tested by the Shapiro–Wilk test. The relationship
between variables was firstly explored by partial Pearson’s correlations controlled by
gender, using log- or square root-transformed variables when necessary, and p-values
≤ 0.01 were considered significant. Two samples t test, or Mann–Whitney test for non-
normally distributed variables, were used to compare groups of subjects classified according
to gender and the TSAT cut-off value of 20% indicative of iron deficiency (Wish, 2006) and
differences with p< 0.05 were considered significant. Statistical analyses were performed
with SPSS 24 (SPSS Inc., Chicago).
RESULTS
All volunteers presented overweight or obesity, 65% high blood pressure, 10% high glucose
and 22% showed bothMetS factors, without significant differences between genders.WHR,
haematocrit, ferritin, sTfR, and the hepatic enzymes were significantly higher in men, while
body fat, abdominal fat, transferrin, leptin and HDL-cholesterol were significantly higher
in women (Table 1). Concerning dietary intake (mean of the three dietary recalls), men
ingested significantly more energy, protein, lipids, cholesterol and calcium than women
(Table 2), although values were rather low for overweight/obese individuals.
Based on these cardiometabolic parameters, several correlations were assessed. BMI
was positively correlated with body fat (r = 0.859, p< 0.001), abdominal fat (r = 0.804,
p< 0.001), and HOMA-IR (r = 0.395, p< 0.006). Transferrin and TSAT were negatively
correlated (r =−0.450, p= 0.002) but there were no correlations between ferritin and
TSAT, ferritin and sTfR, or transferrin and sTfR. In addition, ferritin was positively
correlated with insulin-AUC (r = 0.547, p= 0.008) while TSAT was negatively associated
with WHR (r =−0.385, p= 0.008), insulin (r =−0.551, p< 0.001), and HOMA-IR
(r =−0.586, p< 0.001). The relationship between ferritin and hs-CRP or between other
iron and cardiometabolic markers did not reach the significance level (p> 0.01).
Additionally, the differences in cardiometabolic markers between subjects classified
according to the TSAT cut-off value of 20% were evaluated (Table 3). Subjects in the
low TSAT group (mean ± SD, 15.8 ± 3.4%) presented significantly lower serum iron
and significantly higher RDW, transferrin, TIBC, insulin, and HOMA-IR, and marginally
higher hs-CRP. The differences in HOMA-IR between these groups remained when men
and women were studied separately.
DISCUSSION
In this exploratory study, the relationship between iron metabolism and cardiometabolic
markers was evaluated in adults with overweight or obesity presenting at least another
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Table 1 Body composition, blood pressure, haematological, and biochemical markers of the partici-
pants.
Men Women P value
General characteristics
Number of subjects 27 22 –
Age (years) 42.5± 10.8 42.7± 12.5 0.942
BMI (Kg/m2) 29.8 (32.0;27.9) 29.2 (35.5;26.3) 1.000
WHR 0.99± 0.05 0.88± 0.05 <0.001
WHtR 0.60± 0.07 0.61± 0.08 0.715
Total body fat (%) 27.0± 6.0 39.8± 7.5 <0.001
Abdominal fat (%) 29.3± 6.5 36.9± 8.9 0.001
Systolic pressure (mmHg) 120.8± 11.1 115.1± 14.7 0.144
Diastolic pressure (mmHg) 83.2± 7.8 81.2± 10.1 0.441
Haematological parameters
Haemoglobin (g/dL) 15.7± 1.0 14.0± 0.9 <0.001
Haematocrit (%) 47.0 (48.2;45.5) 43.0 (44.4;40.4) <0.001
MCV (fL) 90.0± 3.8 90.8± 5.9 0.593
RDW (%) 13.5± 0.9 13.2± 0.6 0.169
Iron (µmol/L) 15.0± 5.1 16.6± 6.2 0.328
Ferritin (ng/mL) 160 (224.5;89.0) 34.7 (80.6;24.2) <0.001
Transferrin (g/L) 2.8± 0.3 3.1± 0.4 0.014
TSAT (%) 22.8± 5.3 23.0± 7.4 0.883
TIBC (µmol/L) 70.3± 7.5 76.8± 9.9 0.014
sTfR (µg/mL) 0.99 (1.15;0.88) 0.81 (0.98;0.68) 0.015
Cardiometabolic markers
Glucose (mg/dL) 99.1± 9.1 98.0± 12.0 0.735
Insulin (µU/mL) 7.0± 2.3 7.4± 3.7 0.635
Leptin (ng/mL) 13.5 (28.9;7.2) 33.6 (48.6;26.2) 0.002
Total cholesterol (mg/dL) 199.1± 31.9 208.6± 53.5 0.442
LdL-cholesterol (mg/dL) 123.4± 30.0 122.3± 30.0 0.898
HdL-cholesterol (mg/dL) 44.1± 9.6 53.8± 11.0 0.002
Triglycerides (mg/dL) 135.5 (210.5;106) 119.5 (156.5;85.0) 0.183
hs-CRP (mg/L) 1.34 (3.55;0.62) 3.32(6.60;0.70) 0.117
HOMA-IR 1.62 (2.07;1.36) 1.58 (2.11;1.15) 0.355
Notes.
Values are shown as mean± SD for normal variables, and as median (percentile 75; percentile 25) for non-normal variables.
BMI, Body Mass Index; WHR, Waist to Hip Ratio; WHtR, Waist to Height Ratio; MCV, Mean Corpuscular Volume;
RDW, Red blood cell Distribution Width; TSAT, Transferrin Saturation; TIBC, Total Iron Binding Capacity; sTfR, Soluble
Serum Transferrin Receptor; hs-CRP, high sensitivity-C Reactive Protein; HOMA-IR, Homeostasis Model Assessment In-
dex.
MetS factor. Results, obtained for the whole group as well as for the two groups classified
according to the TSAT cut-off point, show a link between insulin resistance and iron
storage, with low iron transport efficiency.
There is an intense debate on the possibility that iron dysregulation may be involved
in insulin resistance. Population studies have reported associations between ferritin and
cardiovascularmarkers, concluding that high body ironmay be implicated in cardiovascular
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Table 2 Diet characteristics of the participants of the study.
Men Women P valuea
Energy (Kcal) 2055± 565 1674± 620 0.037
Protein (g) 89.4± 17.9 68.3± 26.3 0.003
Carbohydrates (g) 196.4± 58.8 178.0± 77.0 0.368
Fibre (g) 21.7 (32.4;16.0) 18.3 (29.1;14.8) 0.328
Lipids (g) 91.4± 32.3 69.4± 30.6 0.024
Cholesterol (mg) 319.6± 101.7 253.7± 114.8 0.047
SFAb (% energy) 13.0± 2.7 12.5± 2.8 0.568
MUFAc (% energy) 16.8± 4.3 14.7± 5.0 0.159
PUFAd (% energy) 5.8± 1.9 5.9± 1.6 0.811
Calcium (mg) 906.0± 340.0 625.5± 262.4 0.004
Iron (mg) 14.8± 4.7 12.5± 4.7 0.105
Vitamin A (µg) 683 (1210;573) 568 (797;424) 0.133
Vitamin B1 (mg) 1.3 (1.9;1.1) 1.2(1.7;1.0) 0.315
Vitamin B2 (mg) 1.9± 0.6 1.5± 0.6 0.068
Folic acid (µg) 278 (343;193) 259 (286;172) 0.307
Vitamin C (mg) 117 (201;55) 107 (157;73) 0.672
Notes.
aMean values for 3 days dietary recalls. Values are expressed as mean± SD for normal variables, and as median (percentile 75;
percentile 25) for non-normal variables.
bSFA, Saturated Fatty acids.
cMUFA, Monounsaturated Fatty Acids.
dPUFA, Polyunsaturated Fatty Acids.
and diabetes risk (Cheung et al., 2013; Wlazlo et al., 2015). However, in most cases ferritin
values were in normal physiological range, what limits the relevance of the findings.
Similarly, we did not observe either abnormally high or low ferritin values in this study on
subjects with overweight/obesity. We found no association between this marker and body
weight, in contrast with others (Tussing-Humphreys et al., 2009; Aigner, Feldman & Datz,
2014). Nevertheless, since ferritin is an acute phase-protein, it was relevant to determine
whether inflammation was a confounder factor. This was done by analysing hs-CRP, but
the obtained values were below the <2 mg/dL cut-off suggested for normality (Goff Jr et
al., 2014), so no association between ferritin and hs-CRP values was observed. Therefore,
our results do not support that ferritin values were increased by inflammation in these
individuals with overweight/obesity, which is in agreement with other studies (Crist et al.,
2009). Moreover, the values of sTfR, that are unaffected by inflammation and reflect tissue
iron needs, were about 50% lower than those obtained in young iron-deficient women
using the same analytical technique (Blanco-Rojo et al., 2011; Toxqui et al., 2013), which
denotes iron sufficiency in the present work.
The 20% TSAT cut-off value has been proposed to detect iron deficiency (Wish,
2006). In the present study, the higher insulin and HOMA-IR values observed in the
subjects with TSAT<20% are in agreement with some results of the EPIC-InterAct
prospective study (Podmore et al., 2016), the KORA F4 study (Huth et al., 2015), and
the US NHANES (Cheung et al., 2013), all of them showing associations between low TSAT
and prediabetes. Other studies reported that high (Ellervik et al., 2011) or both low and
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Table 3 Body composition, blood pressure, biochemical markers and cardiometabolic indexes accord-
ing to transferrin saturation classification.
Group 1 TSAT≤20% Group 2 TSAT>20% P value
General characteristics
Women (%, n) 50.0 (8) 42.4 (14) 0.789
Age (years) 39.4± 12.8 44.2± 10.9 0.185
BMI (Kg/m2) 30.2 (36.5;26.0) 29.5 (32.2;26.9) 0.714
WHR 0.95± 0.06 0.94± 0.09 0.429
WHtR 0.62± 0.08 0.60± 0.06 0.467
Total body fat (%) 32.9± 10.0 32.1± 8.6 0.794
Abdominal fat (%) 33.2± 9.4 32.2± 8.0 0.683
Systolic pressure (mmHg) 116.8± 10.1 119.1± 14.3 0.577
Diastolic pressure (mmHg) 82.4± 8.0 82.3± 9.6 0.964
Haematological parameters
Haemoglobin (g/dL) 14.5± 1.6 15.2± 1.1 0.087
Haematocrit (%) 45.0 (47.0;39.9) 45.5 (47.7;43.6) 0.175
MCV (fL) 89.5± 4.7 90.7± 4.9 0.442
RDW (%) 14.0± 0.9 13.1± 0.5 0.005
Iron (µmol/L) 10.8± 4.5 17.9± 4.5 <0.001
Ferritin (ng/mL) 36.4 (166.5;22.9) 100.5 (184.3;63.6) 0.072
Transferrin (g/L) 3.1± 0.4 2.8± 0.3 0.006
TSAT (%) 15.8± 3.4 26.1± 4.3 <0.001
TIBC (µmol/L) 78.4± 9.9 70.8± 7.8 0.006
sTfR (µg/mL) 1.02 (1.17;0.74) 0.93 (1.0;0.73) 0.151
Cardiometabolic markers
Glucose (mg/dL) 100.7± 14.0 97.5± 8.2 0.437
Insulin (µU/mL) 8.9± 3.7 6.5± 2.3 0.012
Leptin (ng/mL) 22.7 (42.0;11.2) 22.5 (33.1;9.1) 0.852
Total-cholesterol (mg/dL) 208.2± 55.7 202.6± 36.1 0.678
LdL-cholesterol (mg/dL) 120.4± 27.6 125.4± 30.3 0.593
HdL-cholesterol (mg/dL) 46.8± 11.9 48.9± 11.1 0.554
Triglycerides (mg/dL) 123.5 (215.9;115.1) 135.5 (182.0;79.5) 0.471
hs-CRP (g/L) 3.65 (8.38;8.14) 1.72 (3.33;4.22) 0.060
HOMA-IR 2.01 (3.89;1.54) 1.42 (1.88;1.14) 0.003
Notes.
Values are mean± SD except for non-parametric variables which are expressed as median (percentile 75; percentile 25).
TSAT, Transferrin Saturation; BMI, Body Mass Index; WHR, Waist to Hip Ratio; WHtR, Waist to Height Ratio; MCV,
Mean Corpuscular Volume; RDW, Red blood cell Distribution Width; TIBC, Total Iron Binding Capacity; sTfR, Soluble
Serum Transferrin Receptor; hs-CRP, high sensitivity-C Reactive Protein; HOMA-IR, Homeostasis Model Assessment In-
dex.
high (Stack et al., 2014) TSAT were associated with diabetes risk. This group also presented
slightly higher hs-CRP than the other, although inflammation appears to be low. Therefore,
subjects with overweight/obesity may present insufficient delivery of iron to tissues, which
is related to insulin resistance and probably to a state of subclinical inflammation.
Different proteins play crucial roles in iron metabolism and are essential to guarantee
iron binding for transport and storage, acting as scavengers. In this regard, transferrin
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may be partly glycated (Fernandez-Real, McClain & Manco, 2015) and unable to efficiently
bind and release iron, with possible physiological consequences. Since labile iron acts as a
powerful pro-oxidant, free non-transferrin-bound iron may involve oxidative stress, which
in turn would increase cardiovascular and T2DM risks (Zacharski et al., 2017; Montonen
et al., 2012). Indeed, an elevation of non-transferrin-bound iron has been observed in
patients with T2DM (Lee et al., 2006). This is consistent with the condition of insulin
resistance observed in the present study. Leptin was also elevated in these subjects with
overweight/obesity; although no reference values have been internationally established,
the concentrations obtained here were above the cut-off values for cardiometabolic
abnormalities reported in a Spanish sample of 11,000 subjects, i.e, 6.45 ng/mL for males
and 23.75 ng/mL for females (Gijón-Conde et al., 2015). Nevertheless, this increase in
leptin concentration was not related to any iron marker value. Therefore, considering the
haematological, transferrin, TSAT, sTfR and ferritin results, it can be concluded that iron
status was enough for haemoglobinmaintenance, but transferrin was inefficient. Moreover,
these iron metabolism proteins appear to reflect a situation of altered iron handling and
iron displacement.
This study has several limitations. The main one is the small sample size and the
cross-sectional design, which only allows obtaining relationships and positive/negative
associations but not causality. All participants were of Caucasian origin. Therefore, results
cannot be extrapolated to other races. However, the study also presents several remarkable
strengths: the subjects included in this study were carefully screened; all MetS factors
were monitored; and a variety of cardiometabolic and iron status markers were studied,
including sTfR and possible confounders.
CONCLUSIONS
Characteristics of iron deficiency or iron overload were not observed in subjects with
overweight/obesity exhibiting at least one additional MetS factor. The issue of transferrin
and its binding capacity implication on insulin resistance is much more controversial than
that of ferritin, and our results suggest a complexmetabolic dysregulation. Priority research
should be focused not only on answering the question of whether body iron is increased
or decreased in MetS, obesity and T2DM, but rather if dysmetabolic iron occurs with
delocalization of iron, thus increasing its free radical potential and health consequences.
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